[go: up one dir, main page]

BR0016154A - Depsipeptide and its counterparts for use as immunosuppressants - Google Patents

Depsipeptide and its counterparts for use as immunosuppressants

Info

Publication number
BR0016154A
BR0016154A BR0016154-3A BR0016154A BR0016154A BR 0016154 A BR0016154 A BR 0016154A BR 0016154 A BR0016154 A BR 0016154A BR 0016154 A BR0016154 A BR 0016154A
Authority
BR
Brazil
Prior art keywords
immunosuppressants
grant
depsipeptide
counterparts
suffering
Prior art date
Application number
BR0016154-3A
Other languages
Portuguese (pt)
Inventor
Soren Skov
Original Assignee
Xcyte Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26865325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0016154(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xcyte Therapies Inc filed Critical Xcyte Therapies Inc
Publication of BR0016154A publication Critical patent/BR0016154A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including grant-versus-host disease and enhancement of grant/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion.
BR0016154-3A 1999-12-08 2000-12-06 Depsipeptide and its counterparts for use as immunosuppressants BR0016154A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16973199P 1999-12-08 1999-12-08
US19358200P 2000-03-30 2000-03-30
PCT/US2000/033169 WO2001042282A1 (en) 1999-12-08 2000-12-06 Depsipeptide and congeners thereof for use as immunosuppressants

Publications (1)

Publication Number Publication Date
BR0016154A true BR0016154A (en) 2003-02-25

Family

ID=26865325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016154-3A BR0016154A (en) 1999-12-08 2000-12-06 Depsipeptide and its counterparts for use as immunosuppressants

Country Status (16)

Country Link
US (2) US6403555B1 (en)
EP (3) EP1246839B1 (en)
JP (4) JP4824890B2 (en)
KR (1) KR20020062956A (en)
CN (1) CN1414971A (en)
AT (3) ATE269354T1 (en)
AU (1) AU762525B2 (en)
BR (1) BR0016154A (en)
CA (1) CA2393682C (en)
DE (3) DE60044542D1 (en)
DK (1) DK1438966T3 (en)
ES (3) ES2347284T3 (en)
HK (1) HK1049849B (en)
IL (2) IL149995A0 (en)
PT (1) PT1438966E (en)
WO (1) WO2001042282A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7396665B2 (en) * 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
US6632553B2 (en) * 2001-03-27 2003-10-14 Mti Microfuel Cells, Inc. Methods and apparatuses for managing effluent products in a fuel cell system
DK1426054T3 (en) * 2001-08-21 2011-12-12 Astellas Pharma Inc Medical use of histone deacetylase inhibitor and method for evaluating its antitumor effect
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8883148B2 (en) * 2002-04-26 2014-11-11 Asan Laboratories Company (Cayman), Limited Prevention of joint destruction
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
WO2004017996A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. Arthrodial cartilage extracellular matrix degradation inhibitor
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR20050122210A (en) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 Histone deacetylase inhibitors
US7056883B2 (en) * 2003-06-27 2006-06-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
WO2005007109A2 (en) * 2003-07-09 2005-01-27 Henry Ford Health System Methods and compositions for cancer therapy using a novel adenovirus
US7314862B2 (en) * 2003-09-25 2008-01-01 Astellas Pharma Inc. Antitumor agent
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US20060106049A1 (en) * 2004-11-17 2006-05-18 The University Of Chicago Histone deacetylase inhibitors and methods of use
JP2008524246A (en) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
EP1904452A2 (en) 2005-07-14 2008-04-02 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007030697A2 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by hdac inhibition
JP2009519224A (en) * 2005-11-18 2009-05-14 グロスター ファーマシューティカルズ， インコーポレイテッド Metabolite derivatives of HDAC inhibitor FK228
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
RU2437662C2 (en) 2006-04-07 2011-12-27 Меррион Рисерч Iii Лимитед Solid per oral medication, containing intensifier
WO2008013589A2 (en) 2006-04-24 2008-01-31 Gloucester Pharmaceuticals Treatment of ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
KR20090071598A (en) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 Treatment of liver disease by administration of receptor binding protein (RAP) -conjugates
CA2670223A1 (en) * 2006-11-22 2008-05-29 Karus Therapeutics Limited Depsipeptides and their therapeutic use
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
BRPI0720734A2 (en) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc ROMIDEPSIN PREPARATION
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
MX2009006969A (en) 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Preparation of romidepsin.
WO2008151306A1 (en) * 2007-06-05 2008-12-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Synthesis of cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
CA2709272C (en) * 2007-12-19 2015-03-10 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2723558A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
WO2009141657A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
CA2725278A1 (en) * 2008-05-22 2009-11-26 Karus Therapeutics Limited Depsipeptides and their therapeutic use
WO2010148572A1 (en) * 2009-06-26 2010-12-29 Asan Laboratories Co., Ltd. Method for treating or ameliorating mucocutaneous or ocular toxicities
TWI412359B (en) * 2009-07-07 2013-10-21 Asan Lab Co Ltd Use of histone deacetylase inhibitor in manufacturing a medicament for treating or ameliorating mucocutaneous or ocular toxicities or side effects
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
ES2755909T3 (en) 2010-07-12 2020-04-24 Celgene Corp Solid forms of romidepsin and its uses
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
BR112013017169A2 (en) 2011-01-07 2016-10-04 Merrion Res Iii Ltd iron pharmaceutical compositions for oral administration
EP2762148B1 (en) 2011-09-30 2017-12-27 Tohoku University Depsipeptide as phosphatidylinositol-3-kinase inhibitor and use thereof for treating cancer
AU2013202595B2 (en) 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
TWI772856B (en) 2013-07-19 2022-08-01 美商百健Ｍａ公司 Compositions for modulating tau expression
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
KR20150140177A (en) * 2014-06-05 2015-12-15 한미약품 주식회사 Method of decreasing immunogenicity of protein and pepteide
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN110760564A (en) * 2019-10-16 2020-02-07 菲诺克生物科技(上海)有限公司 Cell cycle detection method and reagent and kit used by same

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
WO1993019778A1 (en) 1992-04-07 1993-10-14 The Scripps Research Institute Method for inducing tolerance to an antigen using butyrate
KR100398819B1 (en) 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 Pharmaceutical composition containing gp39 antagonist
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
CA2191586A1 (en) 1994-06-03 1995-12-14 Carl H. June Methods for selectively stimulating proliferation of t cells
WO1999014241A2 (en) 1997-09-17 1999-03-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5891653A (en) 1995-12-29 1999-04-06 Attfield; Derrick Cecil Method of suppressing graft rejection by means of stress proteins
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6436656B1 (en) 1997-03-03 2002-08-20 Duke University Method for screening a test compound for potential as an immunosuppressive drug candidate
DE19713626A1 (en) * 1997-04-02 1998-10-08 Bayer Ag New thiodepsipeptides to control endoparasites and a simple process for their preparation
WO1998046640A2 (en) 1997-04-15 1998-10-22 Coulter International Corp. Methods and compositions for inducing immunosuppression
CA2302451A1 (en) 1997-09-02 1999-03-11 Japan Energy Corporation Novel cyclic tetrapeptide derivatives and pharmaceutical use thereof
US6355639B1 (en) 1997-09-22 2002-03-12 Sloan-Kettering Institute For Cancer Research Reverse prenyl compounds as immunosuppressants
AU1399199A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Immunosuppressant tetracyclic triterpenes
AU1864999A (en) 1997-12-15 1999-07-05 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
JPH11180873A (en) 1997-12-22 1999-07-06 Kaken Shoyaku Kk NF-κB activity inhibitor
US6211145B1 (en) * 1997-12-25 2001-04-03 Nisshin Flour Milling Co., Ltd. Bicyclic depsipeptides
US6001815A (en) * 1997-12-25 1999-12-14 Nisshin Flour Milling Co., Ltd. Depsipeptides containing N-substituted glycine residue
EP0931792B1 (en) * 1998-01-27 2004-01-07 Nisshin Seifun Group Inc. Depsipeptides containing non-natural amino acids
US6287843B1 (en) 1998-04-03 2001-09-11 Pioneer Hi-Bred International, Inc. Maize histone deacetylases and their use
KR100611265B1 (en) * 1999-01-13 2006-08-10 아스텔라스세이야쿠 가부시키가이샤 New Depsipeptide Compounds

Also Published As

Publication number Publication date
IL149995A (en) 2009-09-01
JP2013107902A (en) 2013-06-06
ATE269354T1 (en) 2004-07-15
HK1070268A1 (en) 2005-06-17
ES2282751T3 (en) 2007-10-16
ES2225282T3 (en) 2005-03-16
ES2347284T3 (en) 2010-10-27
CN1414971A (en) 2003-04-30
IL149995A0 (en) 2002-12-01
JP4824890B2 (en) 2011-11-30
HK1049849B (en) 2004-12-03
KR20020062956A (en) 2002-07-31
ATE353663T1 (en) 2007-03-15
EP1779859B1 (en) 2010-06-09
EP1779859A2 (en) 2007-05-02
DE60011678T2 (en) 2005-07-14
WO2001042282A9 (en) 2002-05-30
EP1438966B1 (en) 2007-02-14
PT1438966E (en) 2007-05-31
DK1438966T3 (en) 2007-06-11
AU2068001A (en) 2001-06-18
CA2393682C (en) 2012-01-31
EP1779859A3 (en) 2007-05-16
EP1438966A3 (en) 2004-08-04
DE60033453T2 (en) 2007-11-29
ATE470447T1 (en) 2010-06-15
HK1049849A1 (en) 2003-05-30
US6403555B1 (en) 2002-06-11
DE60011678D1 (en) 2004-07-22
JP2003516418A (en) 2003-05-13
DE60033453D1 (en) 2007-03-29
EP1438966A2 (en) 2004-07-21
JP2014205714A (en) 2014-10-30
AU762525B2 (en) 2003-06-26
EP1246839A1 (en) 2002-10-09
WO2001042282A1 (en) 2001-06-14
JP2011084585A (en) 2011-04-28
US20020045575A1 (en) 2002-04-18
US6548479B1 (en) 2003-04-15
CA2393682A1 (en) 2001-06-14
EP1246839B1 (en) 2004-06-16
DE60044542D1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
BR0016154A (en) Depsipeptide and its counterparts for use as immunosuppressants
IS2822B (en) Inhibits human phosphatidyl-inositol 3-kinase delta
UA49869C2 (en) NAPHTHYL-SUBSTITUTED BENZIMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHOD FOR TREATMENT (VARIANTS), METHOD FOR INHIBITING HUMAN FACTOR Xa OR IIa
CY1116107T1 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF AUTOMATIC DISEASES, IMMUNO-ALLERGIC DISEASES AND REJECTION OF ORGAN OR TISSUE TRANSFUSION
TR199801919T2 (en) Use of rapamycin derivatives in vascular diseases and foreign tissue transplantation.
ATE373679T1 (en) ANTIMICROBIAL OR ENDOTOXIN NEUTRALIZING POLYPEPTIDE
UA35567C2 (en) Pharmaceutical preparation for treating patients with coagulation impairment, method for treatment, method for pharmaceutical manufacturing
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
ES2193259T3 (en) USE OF AMINOADAMANTAN COMPOUNDS AS IMMUNOR REGULATORS.
ES2156215T3 (en) USE OF A CONJUGATE IN THE TREATMENT AND / OR DIAGNOSIS OF INFLAMMATORY DISEASES.
AU2251302A (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
HUP0000110A2 (en) Pharmaceutical compositions comprising azacyclic, azabicyclic or tetrahydro-pyridine-derivatives suitable for treating pain
WO2003001877A3 (en) Methods for the diagnosis and treatment of cardiac tissue rejection
DK1305047T3 (en) Non-peptidic CCR1 receptor antagonists in combination with cyclosporin A for the treatment of cardiac graft rejection
EP1939203A3 (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
NO20022109D0 (en) Use of treosulfan for the treatment of patients for bone marrow or blood stem cell transplantation
DE59811703D1 (en) Medical or dental treatment chair
MX9801091A (en) Combined use of interleukin-10 and cyclosporin for immunosuppression therapy.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]